The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1356
January 24, 2011
View Complete Issue         Table of Contents 2019 
Ceftaroline Fosamil (Teflaro) - A New IV Cephalosporin
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ceftaroline Fosamil (Teflaro) - A New IV Cephalosporin
January 24, 2011 (Issue: 1356)
The FDA has approved ceftaroline fosamil (Teflaro – Forest), an intravenous (IV) cephalosporin, for treatment of acute bacterial skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA),...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ceftaroline Fosamil (Teflaro) - A New IV Cephalosporin
Article code: 1356a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.